An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis

References

• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17
   PubMed Web of Science ®Google Scholar
• Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24(Suppl 2):31-5
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729-35
   PubMed Web of Science ®Google Scholar
• Day MS, Nam D, Goodman S, et al. Psoriatic arthritis. J Am Acad Orthop Surg 2012;20:28-37
   PubMed Web of Science ®Google Scholar
• Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012;51:571-6
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work Group; Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Black RL, O'Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7
   PubMed Web of Science ®Google Scholar
• Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81
   PubMed Web of Science ®Google Scholar
• Methotrexate Prescribing Information. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf [Last accessed 12 December 2014]
   Google Scholar
• Apremilast Prescribing Information. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205437s000lbl.pdf [Last accessed 1 December 2014]
   Google Scholar
• Gossec L, Smolen J, Ramiro S, et al. European League Against Rheumatism (EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2015 published online 7 December 2015, doi: 10.1136/annrheumdis-2015-208337
   Web of Science ®Google Scholar
• Wells G, Sultan S, Chen L, et al. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), 2009
   Google Scholar
• Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making; 2011; last updated April 2012; available from http://www.nicedsu.org.uk
   Google Scholar
• Jansen J, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health care decision-making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Glenny A, Altman D, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv
   PubMed Web of Science ®Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xxi, 1-329
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. ReadyPrice. Micromedex Solut. Available at: http://www.micromedexsolutions.com/home/dispatch [Last accessed 4 April 2014]
   Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77
   PubMed Web of Science ®Google Scholar
• Wells AF, Edwards CJ, Adebajo AO, et al., eds. Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4). San Diego, CA, USA: American College of Rheumatology, 2013
   Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, Hu C, et al. Long-term 52-week results of PALACE 3, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement. Rheumatology 2014;53(Suppl 1):i138-9
   PubMed Web of Science ®Google Scholar
• Migliore A, Bizzi E, Broccoli S, Lagana B. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol 2012;31:133-7
   PubMed Web of Science ®Google Scholar
• Prashker M, Meenan R. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25
   PubMed Web of Science ®Google Scholar